SPOTLIGHT: Novartis touts positive Diovan data


Novartis is reporting positive data from a Japanese study of Diovan in combination with conventional therapy as a treatment for high blood pressure. New data on the combination therapy revealed a 39 percent reduction in cardiovascular events and a 40 percent reduction of strokes among the 3,000 volunteers in the trial. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.